Keywords: آنتاگونیست گیرنده اندوتلین; ERA; endothelin receptor antagonist; IPAH; idiopathic pulmonary arterial hypertension; PAH; pulmonary arterial hypertension; PDE; phosphodiesterase; SC; subcutaneous; 6MWT; 6-minute walk test; Subcutaneous prostanoid; Pediatric treatment; Pulmonary hypert
مقالات ISI آنتاگونیست گیرنده اندوتلین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آنتاگونیست گیرنده اندوتلین; disease progression; GRIPHON; landmark analysis; SERAPHIN; survival; 6MWD; 6-min walk distance; CI; confidence interval; ERA; endothelin receptor antagonist; HR; hazard ratio; PAH; pulmonary arterial hypertension; PDE-5i; phosphodiesterase type-5 inhibito
Keywords: آنتاگونیست گیرنده اندوتلین; Pulmonary arterial hypertension; Endothelin receptor antagonist; Prostacyclin; Nitric oxide; Dose titration; Specialty pharmacy; ERA; endothelin receptor antagonist; ET-1; endothelin 1; PAH; pulmonary arterial hypertension; PAWP; pulmonary artery wedge pr
Keywords: آنتاگونیست گیرنده اندوتلین; Eisenmenger syndrome; Pulmonary arterial hypertension; Patent ductus arteriosus; Phosphodiesterase type-5 inhibitor; Endothelin receptor antagonist; Heart and lung transplantation;
Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry
Keywords: آنتاگونیست گیرنده اندوتلین; Endothelin-1; Endothelin receptor antagonist; Tandem mass spectrometry; Ultra-high performance liquid chromatography; Plasma;
Keywords: آنتاگونیست گیرنده اندوتلین; Eisenmenger syndrome; Drug therapy; Outcome; Pulmonary arterial hypertension; Congenital heart diseases; Syndrome d'Eisenmenger; Médicament; Pronostic; Cardiopathies congénitales; Hypertension artérielle pulmonaire; CHD; Congenital heart disease; ERA
Keywords: آنتاگونیست گیرنده اندوتلین; comparative efficacy; network meta-analysis; pulmonary arterial hypertension; 6MWD; 6-min walk distance; ERA; endothelin receptor antagonist; FDA; Food and Drug Administration; GRADE; Grading of Recommendations Assessment, Development, and Education; NYHA
Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension
Keywords: آنتاگونیست گیرنده اندوتلین; ERA; endothelin receptor antagonist; LC-MS/MS; high performance liquid chromatography coupled to tandem mass spectrometry; PAH; pulmonary arterial hypertension; PDE5I; phosphodiesterase 5 inhibitor; SPE; solid phase extraction; EMA; European Medicines A
Keywords: آنتاگونیست گیرنده اندوتلین; Hipertensión pulmonar; Hipertensión arterial pulmonar; Revisión; Antagonista del receptor de endotelina; Inhibidores de la fosfodiesterasa tipo 5; Análagos de prostaciclina; Pulmonary hypertension; Pulmonary arterial hypertension; Review; Endothelin r
Keywords: آنتاگونیست گیرنده اندوتلین; Pulmonary hypertension; Pulmonary arterial hypertension; Review; Endothelin receptor antagonist; Phosphodiesterase type 5 inhibitors; Prostacyclin analogs; Hipertensión pulmonar; Hipertensión arterial pulmonar; Revisión; Antagonista del receptor de end
Keywords: آنتاگونیست گیرنده اندوتلین; heart failure with preserved ejection fraction; idiopathic pulmonary arterial hypertension; ERA; endothelin receptor antagonist; HFpEF; heart failure with preserved ejection fraction; IPAH; idiopathic pulmonary arterial hypertension; PAPm; mean pulmonary
Keywords: آنتاگونیست گیرنده اندوتلین; Pulmonary hypertension; Chronic obstructive pulmonary disease; Interstitial lung disease; Obstructive sleep apnea; Endothelin receptor antagonist; Phosphodiesterase inhibitor; Prostacyclin; Soluble guanylate cyclase stimulator;
Keywords: آنتاگونیست گیرنده اندوتلین; Bosentan; Perfluorinated analogues; Metabolic specificity; Phase I metabolism; HLM; Cl; Clearance; CYP; Cytochrome P450; DDI; drug-drug interactions; ERA; Endothelin Receptor Antagonist; ET-1; Endothelin 1; ETA; Endothelin receptor A; ETB; Endothelin rece
Keywords: آنتاگونیست گیرنده اندوتلین; Pulmonary arterial hypertension; Endothelin receptor antagonist; Phosphodiesterase inhibitor; Right heart failure; Cardiac transplant;
Keywords: آنتاگونیست گیرنده اندوتلین; Endothelin receptor antagonist; Pulmonary arterial hypertension; Fetal development; Pulmonary vasculature; ERA; PAH; ET-1; Fetal gene program;
Keywords: آنتاگونیست گیرنده اندوتلین; 6WMD; 6-min walk distance; 6MWT; 6-min walk test; cGMP; cyclic guanosine monophosphate; CTD; connective tissue disease; ERA; endothelin receptor antagonist; ET-1; endothelin-1; HRQoL; health-related quality of life; MCS; mental component summary; MID; min
Keywords: آنتاگونیست گیرنده اندوتلین; Chronic thromboembolic pulmonary hypertension; Pulmonary arterial hypertension; Advanced therapy; Bosentan; Endothelin receptor antagonist;
Keywords: آنتاگونیست گیرنده اندوتلین; Aging; Aged; Renal disease; Endothelin receptor antagonist; Angiotenin converting enzyme inhibitor; Angiotensin receptor blocker; ERA; ARB; Heart failure; Hypertension; Health; Prevention; Chronic disease; Angiotensin; Childhood; Schools; Parents; Educati
Keywords: آنتاگونیست گیرنده اندوتلین; Endothelial dysfunction; Pulmonary arterial hypertension; Prostacyclin; Endothelin receptor antagonist; Type 5 phosphodiesterase inhibitors; Kinase inhibitorsACVRL1, activin A receptor type II-like kinase-1; BMPR2, bone morphogenetic protein receptor type
Keywords: آنتاگونیست گیرنده اندوتلین; 6MWD; 6-min walk distance; AHRQ; Agency for Healthcare Research and Quality; ARIES; Ambrisentan in Pulmonary Arterial Hypertension, Randomized Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study; BNP; brain natriuretic peptide; CB; consensus-bas
Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension
Keywords: آنتاگونیست گیرنده اندوتلین; BMI; body mass index; CI; confidence interval; CO; cardiac output; dPAP; diastolic pulmonary arterial pressure; ERA; endothelin receptor antagonist; FAC; fractional area change; HIV; human immunodeficiency virus; HR; hazard ratio; IQR; interquartile range
CT perfusion imaging of cerebral microcirculatory changes following subarachnoid hemorrhage in rabbits: Specific role of endothelin-1 receptor antagonist
Keywords: آنتاگونیست گیرنده اندوتلین; Subarachnoid hemorrhage; Endothelin receptor antagonist; CT perfusion; Rabbit;
Time-dependent effects of HJP272, an endothelin receptor antagonist, in bleomycin-induced pulmonary fibrosis
Keywords: آنتاگونیست گیرنده اندوتلین; Bleomycin; Endothelin; Endothelin receptor antagonist; Pulmonary fibrosis;
Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study
Keywords: آنتاگونیست گیرنده اندوتلین; Clinical study; Pulmonary hypertension; Soluble guanylate cyclase stimulator; Riociguat; 6MWD; 6-minute walking distance; AE; adverse event; CTEPH; chronic thromboembolic pulmonary hypertension; ERA; endothelin receptor antagonist; LTE; long-term extensio
Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
Keywords: آنتاگونیست گیرنده اندوتلین; endothelin receptor antagonist; focal segmental glomerulosclerosis; irbesartan; nephrotic syndrome; proteinuria; sparsentan;
Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension
Keywords: آنتاگونیست گیرنده اندوتلین; chronic thromboembolic pulmonary hypertension; pulmonary arterial hypertension; sGC stimulator; 6MWD; 6-minute walking distance; ADMA; asymmetric dimethylarginine; AE; adverse event; BH4; tetrahydrobiopterin; BMPR-2; bone morphogenetic protein receptor-2;
Antagonists to endothelin receptor type B promote apoptosis in human pulmonary arterial smooth muscle cells
Keywords: آنتاگونیست گیرنده اندوتلین; Endothelin receptor antagonist; Apoptosis; Pulmonary arterial smooth muscle cell; Pulmonary vascular remodeling;
ReviewRight sided heart failure and pulmonary hypertension: New insights into disease mechanisms and treatment modalities
Keywords: آنتاگونیست گیرنده اندوتلین; cGMP; cyclic guanosine monophosphate; PDE5-I; Prosphodiesterase type 5 inhibitor; PDE5; Prosphodiesterase type 5; 5â²GMP; 5â² Guanosine monophosphate; cAMP; cyclic adenosine monophosphate; ETRA; Endothelin receptor antagonist; AC; adenylate cyclase;
Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention
Keywords: آنتاگونیست گیرنده اندوتلین; Hypertensive nephropathy; Endothelin receptor antagonist; Angiotensin receptor antagonist; Fluid retention
Selective endothelin ETA and dual ETA/ETB receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease
Keywords: آنتاگونیست گیرنده اندوتلین; Serotonin (PubChem CID 5202); Sodium nitroprusside (PubChem CID 11963579); BQ123 (PubChem CID 443289); BQ788 (PubChem CID 23693553); Endothelial dysfunction; Diabetes mellitus; Type 2 diabetes; Endothelin-1; Endothelin a receptor; Endothelin b receptor; E
In Memoriam: Wolfgang Kiowski, M.D. (1949-2012) - Pioneer in clinical endothelin research
Keywords: آنتاگونیست گیرنده اندوتلین; Cardiology; Mentoring; Physiology; Sir William Osler; Heart failure; Endothelin receptor antagonist; Franz Volhard;
Effects of selective endothelin (ET)-A receptor antagonist versus dual ET-A/B receptor antagonist on hearts of streptozotocin-treated diabetic rats
Keywords: آنتاگونیست گیرنده اندوتلین; Diabetic heart; Endothelin receptor antagonist; VEGF signaling; KDR; pAKT
Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: An endothelin receptor antagonist improves the peak PETCO2
Keywords: آنتاگونیست گیرنده اندوتلین; Endothelin receptor antagonist; Cardiopulmonary exercise testing; Pulmonary arterial hypertension; Chronic thromboembolic pulmonary hypertension;
Nrf2 activation: A potential strategy for the prevention of acute mountain sickness
Keywords: آنتاگونیست گیرنده اندوتلین; Nrf2; High altitude sickness; Cerebral; Vascular leak; Calcium channel blockers; Carbon anhydrase inhibitors; Endothelin receptor antagonist; Free radicals;
Tezosentan and Right Ventricular Failure in Patients With Pulmonary Hypertension Undergoing Cardiac Surgery: The TACTICS Trial
Keywords: آنتاگونیست گیرنده اندوتلین; tezosentan; endothelin receptor antagonist; pulmonary hypertension; left-sided heart disease; cardiopulmonary bypass; right ventricular failure
Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy
Keywords: آنتاگونیست گیرنده اندوتلین; Endothelin receptor antagonist; Rat; Pregnancy; Fetal; Neonatal;
Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension
Keywords: آنتاگونیست گیرنده اندوتلین; Sitaxsentan; Pulmonary arterial hypertension; Endothelin; Endothelin receptor antagonist; Functional class6MWD, 6-min walk distance; AE, adverse event; CTD, connective tissue disease; CHD, congenital heart disease; ETRA, endothelin receptor antagonist; PA
Effect of the endothelin receptor antagonist tezosentan on alpha-naphthylthiourea-induced lung injury in rats
Keywords: آنتاگونیست گیرنده اندوتلین; Acute lung injury; Endothelin receptor antagonist; Tezosentan
Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study
Keywords: آنتاگونیست گیرنده اندوتلین; hypertension; pulmonary; pulmonary arterial hypertension; prostacyclin; endothelin receptor antagonist; combination therapy; observational study;
An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension
Keywords: آنتاگونیست گیرنده اندوتلین; ALP; alkaline phosphatase; ALT; alanaine aminotransferase; APTT; activated partial thromboplastin time; AST; aspartate aminotransferase; AUC; area under the curve; BID; twice daily; BSEP; bile salt export pump; CMC; carboxymethylcellulose; DILI; drug-indu
Dual therapy in IPAH and SSc-PAH. A qualitative systematic review
Keywords: آنتاگونیست گیرنده اندوتلین; Pulmonary arterial hypertension; Endothelin receptor antagonist; Phosphodiesterase inhibitor; Prostaglandin; Outcome; Review;
Bosentan improves systemic sclerosis-related peripheral circulation insufficiency
Keywords: آنتاگونیست گیرنده اندوتلین; Endothelin receptor antagonist; Oxidative stress; Nitric oxide bioavailability; Inflammation;
Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension? : A Clinical Perspective
Keywords: آنتاگونیست گیرنده اندوتلین; endothelin receptor antagonist; long-term efficacy; phosphodiesterase inhibitor; prostacyclin; pulmonary arterial hypertension; reviewIPAH, idiopathic pulmonary arterial hypertension; NIH, National Institutes of Health; PAH, pulmonary arterial hypertensio
Sildenafil and Bosentan Improve Arterial Oxygenation During Acute Hypoxic Exercise: A Controlled Laboratory Trial
Keywords: آنتاگونیست گیرنده اندوتلین; phosphodiesterase-5 inhibitor; endothelin receptor antagonist; gas exchange
The separate roles of endothelin receptors participate in remodeling of matrix metalloproteinase and connexin 43 of cardiac fibroblasts in maladaptive response to isoproterenol
Keywords: آنتاگونیست گیرنده اندوتلین; Matrix metalloproteinase; Connexin43; Cardiac fibroblast; Endothelin receptor antagonist; NADPH oxidase; Isoproterenol
Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan
Keywords: آنتاگونیست گیرنده اندوتلین; Prostanoid; Endothelin receptor antagonist; Right heart failure
Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities
Keywords: آنتاگونیست گیرنده اندوتلین; ambrisentan; bosentan; endothelin receptor antagonist; hepatotoxicity; liver function test; propanoic acid; pulmonary hypertension; serum aminotransferase; sitaxsentan; sulfonamideALT, alanine aminotransferase; APAH, associated PAH; ARIES, Ambrisentan in
Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: A role of hyperphosphorylation of PKCε
Keywords: آنتاگونیست گیرنده اندوتلین; Endothelin receptor antagonist; FKBP12.6; SERCA2a; PKCɛ; CPU0213; Vitamin E; H2O2
The endothelin axis in cancer
Keywords: آنتاگونیست گیرنده اندوتلین; Endothelin; Endothelin receptor antagonist; G-protein-coupled receptor; Antitumor therapy
Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension
Keywords: آنتاگونیست گیرنده اندوتلین; Bosentan; Endothelin receptor antagonist; Idiopathic pulmonary arterial hypertensionALT, alanine aminotransferase; AST, aspartate aminotransferase; ET, endothelin; MPAP, mean pulmonary artery pressure; IPAH, idiopathic pulmonary arterial hypertension; ULN